Soluble urokinase-type plasminogen activator receptor (suPAR) is associated with risk for thromboembolic complications and mortality in patients with COVID-19
29 August 2021 (20:24 - 20:33)
Organised by:
About the speaker
The Johns Hopkins University School of Medicine, Baltimore (United States of America)
3 More presentations in this session
Doctor H. Mejia Renteria (Madrid, ES)
Doctor V. Zlochiver (Milwaukee, US)
Professor M. Kruchinina (Novosibirsk, RU)
Access the full session
The Event
ESC Congress 2021 - The Digital Experience
29 August 2021
20:24 CET
